- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Jabbarvand IRAN
Co Author(s): M. Khodaparast A. Salamat Rad H. Hashemian
Back to previous
To evaluate clinical outcomes of Intrastromal corneal inlay implantation using femtosecond laser technology in keratoconic eyes.
Ophthalmology research center, farabi eye hospital, Tehran University of medical sciences
A total of 20 eyes of 20 patients with mean age of 27 (range 16 to 46) entered in the study. According to Alio- shabayek criteria all cases were classified as grade 3 or 4 keratoconus. Inclusion criteria were reduced vision due to keratoconus (corrected distance visual acuity less than 0.5 LogMAR), contact lens intolerance, and central corneal thickness of more than 380 ṁm with no central scar. Annular Intracorneal inlay has an 80 ṁm thickness and 6 mm diameter. We implanted inlays into an intrastromal corneal pocket created using femtosecond laser. Visual, refractive, corneal topography, aberrometry, and pachymetric values were evaluated during one-year follow-up period.Main Outcome Measures were Uncorrected and corrected distance visual acuity, manifest refraction, keratometry, aberrometry, and pachymetry.
Uncorrected distance visual acuity improved significantly one month after operation while corrected distance visual acuity improved nonsignificantly. Both spherical and cylindrical components of refraction reduced significantly after one month. There was a significant reduction in keratometry (mean 5.6 D)in the first month too. No significant changes were detected in these parameters between first and 12th months. A statistically significant increase in primary spherical aberration was found 1 month after surgery. Total higher order aberrations and coma reduced non significantly through the follow up period. In one patient with severe keratoconus we exchanged the Inlay with MyoRing because of residual myopia and patient dissatisfaction.
Annular intracorneal stromal inlay implantation using femtosecond technology in keratoconus has acceptable safety and efficacy profile.